Soni Anju, Walters Pamela
South London and Maudsley NHS Foundation Trust, London, UK.
Int J Prison Health. 2019 Aug 27;16(1):67-77. doi: 10.1108/IJPH-01-2019-0004.
Electronic medical case files of male prisoners in a category B prison in London were studied to establish a prevalence during an eight-month period of the use of and the reasons for prescribing gabapentinoids in prison and also to establish prescribing standards in prison and compliance with these. In addition, the prevalence of co-prescription of gabapentinoids with opioids and antidepressants, particularly tricyclic antidepressants such as amitriptyline, was also assessed in light of the increased risk of respiratory depression resulting in death when these drugs are used in combination. The paper aims to discuss these issues.
DESIGN/METHODOLOGY/APPROACH: A retrospective, SystmOne case-file based survey was undertaken searching by SNOMED CT supplemented by examination of free text, in a category B prison for males (Capacity 1,500 prisoners; Average turnover of prisoners up to 6,000 per year), to establish practice standards related to the prescription of Gabapentinoids in the prison and determine compliance with these.
In total, 109 cases were identified of prisoners having been prescribed gabapentinoids, pregabalin in 66 cases (61 per cent) and gabapentin in 43 cases (39 per cent). In 36 cases (33 per cent) prescriptions were for unlicensed indications. This in fact represented 50 per cent of the cases where the indications were documented. In 51 cases (47 per cent) gabapentinoids were prescribed with an opioid substitute. In 14 cases (13 per cent), prescribed gabapentinoids were diverted to other prisoners.
The initiation of gabapentinoids in prison should be avoided. For prisoners who are also receiving opioid substitutes or are abusing opiates, it may be unsafe to continue on gabapentinoids. Issues raised by this study are likely to apply to other prisons, secure forensic psychiatric facilities and indeed community mental health and primary care as well.
Risk of dependance on gabapentinoids including risk of mortality when taken with opioids and opioid substitutes.
ORIGINALITY/VALUE: This is an original study conducted at a category B prison in London.
对伦敦一所B类监狱男性囚犯的电子病历进行研究,以确定在八个月期间监狱中加巴喷丁类药物的使用情况、处方原因,并制定监狱中的处方标准以及对这些标准的遵守情况。此外,鉴于加巴喷丁类药物与阿片类药物和抗抑郁药(特别是三环类抗抑郁药如阿米替林)联合使用会增加导致呼吸抑制死亡的风险,还评估了加巴喷丁类药物与阿片类药物和抗抑郁药联合处方的情况。本文旨在讨论这些问题。
设计/方法/途径:在一所男性B类监狱(容量为1500名囚犯;每年囚犯平均周转量达6000人)进行了一项基于SystmOne病例档案的回顾性调查,通过SNOMED CT进行搜索,并辅以自由文本检查,以确立与监狱中加巴喷丁类药物处方相关的实践标准,并确定对这些标准的遵守情况。
总共确定了109例囚犯被开具加巴喷丁类药物的病例,其中66例(61%)为普瑞巴林,43例(39%)为加巴喷丁。在36例(33%)病例中,处方用于未获许可的适应症。这实际上占记录有适应症病例的50%。在51例(47%)病例中,加巴喷丁类药物与阿片类替代药物联合处方。在14例(13%)病例中,开具的加巴喷丁类药物被转给其他囚犯。
应避免在监狱中开始使用加巴喷丁类药物。对于同时接受阿片类替代药物或滥用阿片类药物的囚犯,继续使用加巴喷丁类药物可能不安全。本研究提出的问题可能也适用于其他监狱、安全的法医精神病设施,实际上也适用于社区心理健康和初级保健。
对加巴喷丁类药物产生依赖的风险,包括与阿片类药物和阿片类替代药物一起服用时的死亡风险。
原创性/价值:这是在伦敦一所B类监狱进行的一项原创性研究。